Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma

Journal of Neuro-Oncology

Volumn 133, Issue 3, 2017, Pages 595-602

  Fang, Penny ^a   Jiang, Wen ^a   Allen, Pamela ^a   Glitza, Isabella ^a   Guha, Nandita ^a   Hwu, Patrick ^a   Ghia, Amol ^a   Phan, Jack ^a   Mahajan, Anita ^a   Tawbi, Hussein ^a   Li, Jing ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

CTLA 4 inhibitor; Immunotherapy; Ipilimumab; Metastatic melanoma; PD 1 inhibitor; Radiation necrosis

Indexed keywords

BEVACIZUMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DABRAFENIB; DACARBAZINE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IPILIMUMAB; PACLITAXEL; PEMBROLIZUMAB; SORAFENIB; TEMOZOLOMIDE; TRAMETINIB; VEMURAFENIB; VINBLASTINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADOLESCENT; AGED; ARTICLE; BRAIN DISEASE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; OVERALL SURVIVAL; RADIATION NECROSIS; RETROSPECTIVE STUDY; STEREOTACTIC RADIOSURGERY; SYSTEMIC THERAPY; TREATMENT DURATION; VERY ELDERLY; ADULT; ANTAGONISTS AND INHIBITORS; BRAIN TUMOR; FOLLOW UP; IMMUNOTHERAPY; MELANOMA; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NECROSIS; RADIATION INJURY; RADIOSURGERY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; CTLA-4 ANTIGEN; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; IPILIMUMAB; MALE; MELANOMA; MIDDLE AGED; NECROSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; RADIATION INJURIES; RADIOSURGERY; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 85019251771     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-017-2470-4     Document Type: Article

References (20)

1. Staudt M, Lasithiotakis K, Leiter U, Meier F, Eigentler T, Bamberg M et al (2010) Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer 102:1213–1218. doi:10.1038/sj.bjc.6605622
2. Chiarion-Sileni V, Guida M, Ridolfi L, Romanini A, Del Bianco P, Pigozzo J et al (2011) Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens. Br J Cancer 104:1816–1821. doi:10.1038/bjc.2011.178
3. Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG et al (2009) Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10:1037–1044. doi:10.1016/S1470-2045(09)70263-3
4. Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK et al (2016) Effect of radiosurgery alone vs. radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA 316:401–409. doi:10.1001/jama.2016.9839
5. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB et al (2012) Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13:1087–1095. doi:10.1016/S1470-2045(12)70431-X
6. Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M et al (2016) Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 17:976–983. doi:10.1016/S1470-2045(16)30053-5
7. Queirolo P, Spagnolo F, Ascierto PA, Simeone E, Marchetti P, Scoppola A et al (2014) Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. J Neurooncol 118:109–116. doi:10.1007/s11060-014-1400-y
8. Kohutek ZA, Yamada Y, Chan TA, Brennan CW, Tabar V, Gutin PH et al (2015) Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases. J Neurooncol 125:149–156. doi:10.1007/s11060-015-1881-3
9. Colaco RJ, Martin P, Kluger HM, Yu JB, Chiang VL (2016) Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases? J Neurosurg 125:17–23. doi:10.3171/2015.6.JNS142763
10. Patel KR, Shoukat S, Oliver DE, Chowdhary M, Rizzo M, Lawson DH et al (2015) Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases. Am J Clin Oncol. doi:10.1097/COC.0000000000000199
11. Schoenfeld JD, Mahadevan A, Floyd SR, Dyer MA, Catalano PJ, Alexander BM et al (2015) Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review. J Immunother Cancer 3:50. doi:10.1186/s40425-015-0095-8
12. Du Four S, Hong A, Chan M, Charakidis M, Duerinck J, Wilgenhof S et al (2014) Symptomatic histologically proven necrosis of brain following stereotactic radiation and ipilimumab in six lesions in four melanoma patients. Case Rep Oncol Med 2014:417913. doi:10.1155/2014/417913
13. Shaw E, Scott C, Souhami L, Dinapoli R, Kline R, Loeffler J et al (2000) Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90–05. Int J Radiat Oncol Biol Phys 47:291–298
14. Voong KR, Farnia B, Wang Q, Luo D, McAleer MF, Rao G et al (2015) Gamma knife stereotactic radiosurgery in the treatment of brainstem metastases: the MD Anderson experience. Neuro-Oncol Pract 2:40–47. doi:10.1093/nop/npu032
15. Tazi K, Hathaway A, Chiuzan C, Shirai K (2015) Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery. Cancer Med 4:1–6. doi:10.1002/cam4.315
16. Kiess AP, Wolchok JD, Barker CA, Postow MA, Tabar V, Huse JT et al (2015) Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys 92:368–375. doi:10.1016/j.ijrobp.2015.01.004
17. Qian JM, Yu JB, Kluger HM, Chiang VLS (2016) Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Cancer 122:3051–3058. doi:10.1002/cncr.30138
18. Sneed PK, Mendez J, Vemer-van den Hoek JGM, Seymour ZA, Ma L, Molinaro AM et al (2015) Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors. J Neurosurg 123:373–386. doi:10.3171/2014.10.JNS141610
19. Patel KR, Chowdhary M, Switchenko JM, Kudchadkar R, Lawson DH, Cassidy RJ et al (2016) BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis. Melanoma Res 26:387–394. doi:10.1097/CMR.0000000000000268
20. Patel BG, Ahmed KA, Johnstone PAS, Yu H-HM, Etame AB (2016) Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases. Melanoma Res 26:382–386. doi:10.1097/CMR.0000000000000250